3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Meet Veristat at the Orphan Drug Congress, 14-17 November 2022
Whether you have a compound and need to get started on your IND, or want to recruit patients quickly to get your early phase trials running or just need medical writing or biostatistical support for your programs - Veristat can help. We provide impactful solutions on both a full-service or functional service basis.
Veristat team members Mariska van der Heijden, VP of European Sales and Balma Gil Gimeno, Business Development Director, will be at the venue— ready to listen to your needs and share Veristat’s expertise in orphan drug development.
Schedule A Meeting
If you’d like to talk to us, simply schedule a meeting by filling out the form on the right. Find out how we can help you advance your next clinical trial or regulatory submission to a successful outcome or learn more about our capabilities.
Virtual Conference Details
Website: https://www.terrapinn.com/conference/world-orphan-drug-congress/index.stm
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...